Tim Wilsdon recently presented at an education forum at ISPOR Latin America, talking about the challenges that gene therapy poses for value assessment and considerations for the future.
For more information about the conference, click here.
An analysis of the effect of drug pricing provisions in the Build Back Better Act on pharmaceutical innovation
Charles River Associates has previously assessed the implications of proposals to implement international reference pricing in the US and found they would...